Curt LaBelle

Dr. LaBelle has been investing in and working with life science companies for over 20 years. Since 2015, he has been President of the Global Health Investment Fund (GHIF). GHIF is a pioneering impact fund with a proven record of generating attractive financial returns and tangible impact. The fund works to facilitate access to therapeutics and diagnostics among low-income populations. Dr. LaBelle also works with the AXA Prime Impact Fund and serves as a Board member for Alydia Health, Atomo Diagnostics (ASX: AT1), Atticus Medical, Eyenovia (Nasdaq: EYEN), and Z Optics. Dr. LaBelle received his M.D. and M.B.A from Columbia University.